Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, USA.
Department of Haematology, School of Medicine, St. James's Hospital, Trinity College, Dublin, Ireland.
Br J Haematol. 2024 May;204(5):1590-1592. doi: 10.1111/bjh.19439. Epub 2024 Apr 2.
Chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of multiple myeloma (MM) has fundamentally changed the relapsed and refractory therapeutic landscape, but the disease remains incurable. Two CAR-T products, idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti), have been FDA- and EMA-approved for the treatment of relapsed/refractory MM (RRMM); both target B-cell maturation antigen (BCMA), a surface glycoprotein highly expressed on MM cells. Despite deep and durable responses following CAR-T therapy, most patients will need subsequent treatment, and the optimal next-line therapy is presently unclear. Commentary on: Liu et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br J Haematol 2024;204:1780-1789.
嵌合抗原受体 T 细胞（CAR-T）疗法治疗多发性骨髓瘤（MM）从根本上改变了复发和难治性的治疗格局，但该病仍无法治愈。两种 CAR-T 产品，idecabtagene vicleucel（ide-cel；Abecma）和 cilta-cabtagene autoleucel（cilta-cel，Carvykti），已获得 FDA 和 EMA 批准用于治疗复发/难治性 MM（RRMM）；均靶向 B 细胞成熟抗原（BCMA），这是一种在 MM 细胞上高度表达的表面糖蛋白。尽管 CAR-T 治疗后会出现深度和持久的应答，但大多数患者仍需要后续治疗，目前尚不清楚最佳的后续治疗方案。述评：Liu 等人。BCMA 特异性 CAR-T 治疗后接受挽救治疗的多发性骨髓瘤患者的结局：LEGEND-2 的回顾性分析。英国血液学杂志 2024；204：1780-1789。
